125 related articles for article (PubMed ID: 11748473)
1. Combined effects of lutenizing hormone-releasing hormone analogue with antiestrogen on rat mammary tumors.
Matsumoto H; Koibuchi Y; Horiguchi J; Iino Y; Morishita Y
Oncol Rep; 2002; 9(1):145-51. PubMed ID: 11748473
[TBL] [Abstract][Full Text] [Related]
2. Effects of sequential and combined immuno-endocrine therapies using OK-432 (Picibanil) and tamoxifen on the growth of 7,12-dimethylbenz [alpha] anthracene-induced rat mammary carcinoma.
Iino Y; Yoshida M; Tago T; Owada S; Sugamata N; Horiuchi R
Jpn J Clin Oncol; 1991 Feb; 21(1):35-8. PubMed ID: 1906118
[TBL] [Abstract][Full Text] [Related]
3. Chemoendocrine therapy in DMBA-induced rat mammary carcinoma.
Morimoto T; Yamamoto H; Komaki K; Konishi N; Tanaka T; Yamakawa T; Mori T; Sasa M; Monden Y
Tokushima J Exp Med; 1990 Dec; 37(3-4):59-68. PubMed ID: 2128782
[TBL] [Abstract][Full Text] [Related]
4. [Effect of tamoxifen plus octreotide on DMBA-induced mammary tumors in rats].
Zeng XZ; Yao ZX
Zhonghua Yi Xue Za Zhi; 2005 Jan; 85(1):28-32. PubMed ID: 15808071
[TBL] [Abstract][Full Text] [Related]
5. Effects of sequential and combined endocrine therapies on the growth of 7,12-dimethylbenz [alpha] anthracene-induced rat mammary carcinoma.
Iino Y; Ogawa T; Yoshida M; Ishikawa H; Izuo M; Takikawa H
Jpn J Clin Oncol; 1990 Sep; 20(3):259-62. PubMed ID: 2147726
[TBL] [Abstract][Full Text] [Related]
6. Effect of rosiglitazone on N-nitroso-N-methylurea-induced mammary tumors in rat.
Núñez M; Martín G; Cocca C; Mohamad N; Gutiérrez A; Cricco G; Medina V; Rivera E; Croci M; Crescenti E; Bergoc R
Anticancer Res; 2006; 26(3A):2113-22. PubMed ID: 16827153
[TBL] [Abstract][Full Text] [Related]
7. Effects of tamoxifen and melatonin on mammary gland cancer induced by N-methyl-N-nitrosourea and by 7,12-dimethylbenz(a)anthracene, respectively, in female Sprague-Dawley rats.
Kubatka P; Bojková B; M ciková-Kalická K; Mníchová-Chamilová M; Adámeková E; Ahlers I; Ahlersová E; Cermáková M
Folia Biol (Praha); 2001; 47(1):5-10. PubMed ID: 11232869
[TBL] [Abstract][Full Text] [Related]
8. Sequential hormone therapy with medroxyprogesterone acetate for 7, 12-dimethylbenz [alpha] anthracene-induced rat mammary tumors.
Iino Y; Ishikawa H; Izuo M; Takikawa H
Jpn J Clin Oncol; 1989 Mar; 19(1):45-50. PubMed ID: 2522157
[TBL] [Abstract][Full Text] [Related]
9. An antiangiogenic urokinase-derived peptide combined with tamoxifen decreases tumor growth and metastasis in a syngeneic model of breast cancer.
Guo Y; Mazar AP; Lebrun JJ; Rabbani SA
Cancer Res; 2002 Aug; 62(16):4678-84. PubMed ID: 12183425
[TBL] [Abstract][Full Text] [Related]
10. [Experimental study of combination medical endocrine therapy on DMBA-induced mammary tumor, with special reference to the effect of drug-dose on various factors].
Kosaka A; Yamashita A
Gan To Kagaku Ryoho; 1992 Jan; 19(1):75-81. PubMed ID: 1530907
[TBL] [Abstract][Full Text] [Related]
11. The mechanisms of antitumor effects of luteinizing hormone-releasing hormone agonist (buserelin) in 7, 12-dimethylbenz(a)anthracene-induced rat mammary cancer.
Koibuchi Y; Sugamata N; Iino Y; Yokoe T; Andoh T; Maemura M; Takei H; Horiguchi J; Matsumoto H; Morishita Y
Int J Mol Med; 1999 Aug; 4(2):145-8. PubMed ID: 10402480
[TBL] [Abstract][Full Text] [Related]
12. A novel aromatase inhibitor, vorozole, shows antitumor activity and a decrease of tissue insulin-like growth factor-I level in 7, 12-dimethylbenz[a]anthracene-induced rat mammary tumors.
Sugamata N; Koibuchi Y; Iino Y; Morishita Y
Int J Oncol; 1999 Feb; 14(2):259-63. PubMed ID: 9917500
[TBL] [Abstract][Full Text] [Related]
13. Effects of alterations in early hormonal environment on development and hormone dependency of carcinogen-induced mammary tumors in rats.
Sylvester PW; Aylsworth CF; Van Vugt DA; Meites J
Cancer Res; 1983 Nov; 43(11):5342-6. PubMed ID: 6413057
[TBL] [Abstract][Full Text] [Related]
14. Potentiation of the antitumor effect of tamoxifen by combination with the antiprogestin onapristone.
Nishino T; Ishibashi K; Hirtreiter C; Nishino Y
J Steroid Biochem Mol Biol; 2009 Sep; 116(3-5):187-90. PubMed ID: 19500671
[TBL] [Abstract][Full Text] [Related]
15. Tamoxifen-induced antitumorigenic/antiestrogenic action synergized by a selective aryl hydrocarbon receptor modulator.
McDougal A; Wormke M; Calvin J; Safe S
Cancer Res; 2001 May; 61(10):3902-7. PubMed ID: 11358803
[TBL] [Abstract][Full Text] [Related]
16. Endocrine and antitumor effects of combined treatment with an antiprogestin and antiestrogen or luteinizing hormone-releasing hormone agonist in female rats bearing mammary tumors.
Bakker GH; Setyono-Han B; Portengen H; De Jong FH; Foekens JA; Klijn JG
Endocrinology; 1989 Sep; 125(3):1593-8. PubMed ID: 2527151
[TBL] [Abstract][Full Text] [Related]
17. Effective sequential administration of tamoxifen and medroxyprogesterone acetate for 7,12-dimethylbenz[a-anthracene-induced rat mammary tumors in relation to hormone receptors.
Tominaga T; Yoshida Y; Kitamura M; Kosaki G
Jpn J Cancer Res; 1985 Nov; 76(11):1120-5. PubMed ID: 2935517
[TBL] [Abstract][Full Text] [Related]
18. Antagonistic effects of styrylpyrone derivative (SPD) on 7,12-dimethylbenzanthracene-induced rat mammary tumors.
Hawariah A; Stanslas J
In Vivo; 1998; 12(4):403-10. PubMed ID: 9706492
[TBL] [Abstract][Full Text] [Related]
19. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model.
Gottardis MM; Jordan VC
Cancer Res; 1987 Aug; 47(15):4020-4. PubMed ID: 3607747
[TBL] [Abstract][Full Text] [Related]
20. Induction of tamoxifen-dependent rat mammary tumors.
Zimniski SJ; Warren RC
Cancer Res; 1993 Jul; 53(13):2937-9. PubMed ID: 8319198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
